deltatrials
Completed PHASE1 NCT00790153

To Evaluate the Hormonal Response to Low Blood Sugar After a Single Oral Dose of AZD1656 Suspension

A Randomized, Open, Two-Way Cross-Over, Single-Centre, Phase I Study to Assess the Counter Regulatory Response During Hypoglycaemia in Healthy Male Volunteers After a Single Oral Dose of AZD1656 Suspension in Comparison With Insulin Infusion

Sponsor: AstraZeneca

Conditions Type 2 Diabetes
Interventions AZD1656 Insulin
Updated 5 times since 2017 Last updated: Apr 9, 2009 Started: Nov 30, 2008 Completion: Feb 28, 2009

A PHASE1 clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 5 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Chula Vista, United States